Atox Bio: Reltecimod passes Futility Analysis and will continue Phase 3
Atox Bio announced that Reltecimod (previously AB103) successfully completed pre-specified futility analysis in patients with Necrotizing Soft Tissue Infections and will continue…
Read More...
Read More...